A cure may be available by the end of the decade: BioNTech successfully tests cancer vaccine
Kyiv • UNN
BioNTech reports successful trials of a cancer vaccine, plans to continue the study until 2029, and hopes to get approval by 2030. The vaccine, which uses personalized mRNA technology, has demonstrated tumor shrinkage in clinical trials.
BioNTech, the company that developed the Pfizer coronavirus vaccine, has announced successful trials of a cancer vaccine. This was stated in an interview with Bild am Sonntag by one of the founders of BioNTech, Ugur Shahin, UNN reports .
Details
According to him, the company plans to obtain research data for a number of other therapeutic approaches between 2025 and 2029. It also hopes to have the first personalized mRNA-based cancer vaccines approved by 2030.
SEE ALSO: Lung cancer pills cut risk of death in half - study
We take blood and tumor samples from the patient, and after four weeks we inject an individualized vaccine... Ideally, it is not 100, but tens of thousands of patients a year
Supplement
It is known that in October the company announced the results of the first clinical trial of a combination of an mRNA-based cancer vaccine and CAR T cell therapy. Tumors stopped growing in almost all patients and shrank in almost two-thirds.
This approach can make the immune system specifically find and destroy the tumor with the help of an army of special warriors
The scientist is confident that combination therapy of different approaches is the strategy of the future.
I am confident that over the next few years ADCS will be increasingly used as targeted chemotherapy, rather than classical chemotherapy, for many cancer indications
Recall
Johnson & Johnson said the U.S. Food and Drug Administration (FDA) has approved its therapy for patients with a hard-to-treat type of blood cancer.
SEE ALSO: BioNTech and OncoC4 announce promising results from lung cancer antibody trial
